Edgewise Therapeutics (EWTX) corrects CFO option grant price
Rhea-AI Filing Summary
Edgewise Therapeutics, Inc. reported that Chief Financial Officer Michael Nofi received a grant of 48,750 stock options on August 12, 2026. These options have an exercise price of $43.56 per share, reflecting the fair market value on the grant date, and expire on August 12, 2036. The amendment clarifies that an earlier filing incorrectly showed a $0.00 exercise price due to a clerical error. According to the vesting terms, 1/48 of the options vest each month beginning on September 12, 2026, contingent on his continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Nofi Michael
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1 | 48,750 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 48,750 shares (Direct)
Footnotes (1)
- F1. 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.
Key Figures
Options Granted: 48,750 options
Exercise Price: $43.56 per share
Shares Underlying Options: 48,750 shares
+4 more
7 metrics
Options Granted
48,750 options
Stock Option (Right to Buy) grant to CFO Michael Nofi on August 12, 2026
Exercise Price
$43.56 per share
Corrected exercise price reflecting fair market value on grant date
Shares Underlying Options
48,750 shares
Common stock underlying the reported stock option award
Options After Transaction
48,750 options
Total derivative securities held from this grant following the reported acquisition
Vesting Rate
1/48 per month
Monthly vesting of the option beginning September 12, 2026
Vesting Start Date
September 12, 2026
First vesting date for the monthly installments of the option
Expiration Date
August 12, 2036
Date after which the granted options are no longer exercisable
Key Terms
Stock Option (Right to Buy), exercise price, vesting, expiration date, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title is listed as Stock Option (Right to Buy)"
exercise price financial
"The correct exercise price is $43.56, which reflects the fair market value"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"1/48th of the shares subject to the option vest each month"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date is reported as 2036-08-12 for the option grant"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
fair market value financial
"which reflects the fair market value of the underlying security on the date"
The price a willing buyer and a willing seller would agree on for an asset or security when neither is under pressure and both have access to the same information. Think of it as the market’s neutral estimate of what something is worth, like the price two neighbors would settle on for a car after comparing similar listings. Investors care because fair market value guides buying and selling decisions, tax reporting, portfolio valuation, and how accurately company assets are reflected in financial statements.
FAQ
What insider transaction did EWTX report for CFO Michael Nofi in this Form 4/A?
The filing reports a grant of 48,750 stock options to CFO Michael Nofi on August 12, 2026. These options are a compensation award with a defined vesting schedule and a fixed exercise price.
What is the corrected exercise price of Michael Nofi’s options in EWTX?
The corrected exercise price is $43.56 per share, matching the fair market value on the grant date. The amendment was filed because the original report mistakenly showed a $0.00 exercise price.
How many Edgewise Therapeutics (EWTX) options were granted to the CFO?
Michael Nofi was granted 48,750 stock options for Edgewise Therapeutics common stock. Following this grant, his reported derivative holdings from this award total 48,750 options, all subject to future vesting conditions.
What is the vesting schedule for Michael Nofi’s EWTX stock options?
The options vest in monthly installments of 1/48 of the total grant starting September 12, 2026. Vesting on each date is conditioned on Mr. Nofi continuing as a service provider to the company.
When do Michael Nofi’s EWTX stock options expire?
The stock options granted to Michael Nofi have an expiration date of August 12, 2036. After this date, any unexercised options from this grant will no longer be exercisable.
Did Edgewise Therapeutics indicate a Rule 10b5-1 trading plan for this EWTX option grant?
No. The filing’s Rule 10b5-1 indicator is unchecked, and there is no footnote stating that the option grant occurred under a Rule 10b5-1 trading plan or similar arrangement.
AI-generated analysis. How Rhea-AI works. Not financial advice.
